NCT06647680 2026-03-06
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
The Affiliated Hospital of Qingdao University
Phase 2 Recruiting
Clinical Trials
39 trialsNCT06452602 2026-02-27
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT05673772 2026-02-12
SOLAR
Kyungpook National University Hospital
Phase 2 Active not recruiting
NCT07385664 2026-02-04
FAIR
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT07386704 2026-02-04
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
Peking University First Hospital
Phase 2 Enrolling by invitation
NCT03322995 2026-01-08
PANC
Medical College of Wisconsin
Phase 2 Recruiting
NCT05358704 2025-12-04
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
Rutgers, The State University of New Jersey
Phase 2 Suspended
NCT03110926 2025-09-12
Induction Chemotherapy for Locally Advanced Esophageal Cancer
University of Rochester
Phase 2 Active not recruiting
NCT06048913 2025-07-04
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Completed
NCT07026422 2025-06-18
Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT04821765 2025-05-30
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT05944809 2025-01-24
The Effect of Prophylactic TPO Combined with BMS-IMRT to Esophageal Cancer Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT05546411 2024-12-17
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT06429839 2024-05-28
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06410651 2024-05-13
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT04124601 2024-04-23
CHINOREC
Medical University of Vienna
Phase 2 Completed
NCT04543695 2024-03-26
A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Active not recruiting
NCT06239870 2024-02-02
ESTIMATE
Yunnan Cancer Hospital
Phase 2 Unknown
NCT02676349 2023-09-28
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Phase 2 Active not recruiting
NCT05450029 2023-09-26
SILAR
Sun Yat-sen University
Phase 2 Recruiting
NCT01470417 2023-08-22
GAIN-1
University of Florida
Phase 2 Completed
NCT05528367 2022-09-06
Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT01889303 2022-02-14
Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer
Wuhan University
Phase 2 Unknown
NCT04418895 2021-11-10
Neoadjuvant Therapy for Localized Rectal Adenocarcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04423965 2021-03-23
A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT01362127 2020-02-26
NeoRes
Karolinska University Hospital
Phase 2 Completed
NCT02301143 2019-03-20
LAPACT
Celgene
Phase 2 Completed
NCT03725254 2019-01-23
CRT Versus Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of CRC
Fudan University
Phase 2 Unknown
NCT03223662 2018-10-30
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01037049 2018-09-17
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT03579004 2018-07-06
Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer
Russian Academy of Medical Sciences
Phase 2 Unknown
NCT03085992 2018-03-14
TRUST
Azienda Ospedaliero, Universitaria Pisana
Phase 2 Completed
NCT02439593 2017-08-01
HEATPAC
Kantonsspital Aarau
Phase 2 Unknown
NCT01507103 2017-01-13
SPRINT
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00278694 2016-09-29
LARC-RRP
Oslo University Hospital
Phase 2 Completed
NCT01551641 2016-02-17
Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer
Changzhou No.2 People's Hospital
Phase 2 Unknown
NCT00512304 2013-03-05
TRACE
University Hospital, Rouen
Phase 2 Completed
NCT00578201 2011-03-31
FOLFOX
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT00808379 2008-12-15
Concurrent Chemo-Radiotherapy Versus Radiotherapy With Boost in Locally Advanced Unresectable Rectal Cancers
Tata Memorial Hospital
Phase 2 Unknown